Overview
- Novartis is investing about $39 million in the first, semi-automated production line to manufacture radioligand therapies in Halle.
- The plant is slated to start production by late 2027, with the site designed for potential expansion to additional lines.
- About 25 highly qualified jobs are planned at the Neustadt industrial area location along Weststraße, supported by proximity to Leipzig/Halle Airport and major nuclear medicine centers.
- Saxony-Anhalt will fund skilled‑worker measures and provide an environmental subsidy to support the project.
- Clinicians in Magdeburg expect faster, more reliable supplies of targeted cancer drugs, noting the therapy is already in regular use at the university hospital.